Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Main Article Content

Neil Korman
Kim Papp
Jerry Bagel
Peter Foley
Akimichi Morita
Subhashis Banerjee
Elizabeth Colston
Tao Wang
John Throup
Diamant Thaci

Keywords

Deucravacitinib, JAK Inhibitor, Psoriasis, phase 3 trial

Abstract

N/A

References

1. Burke JR et al. Sci Transl Med 2019;11:1-16.
2. Wrobleski ST et al. J Med Chem 2019;62:8973-8995.
3. Papp K et al. N Engl J Med 2018;379:1313-1321.
4. Mease PJ et al. Presented at the Annual Scientific Meeting of the American College of Rheumatology; November 5-9, 2020

Most read articles by the same author(s)

1 2 3 4 5 > >>